نتایج جستجو برای: canagliflozin
تعداد نتایج: 684 فیلتر نتایج به سال:
Introduction: Cardiovascular disease, diabetes, and fatty liver are now considered the major causes of mortality in developing countries. The present study investigates the effect of twelve weeks of combined training with and without canagliflozin consumption on fetuin-A and fetuin B in type 2 diabetic men. Materials and Methods: Forty- four men (25-40 years ) who had type two diabitiac were r...
Diabetes is highly prevalent in kidney transplant recipients (KTR). Simultaneous pancreas-kidney transplant recipients (SPKTR) are also at risk for developing type 2 diabetes following transplantation, when insulin secretionmaybe insufficient to maintain normoglycemia. Transplantspecific risk factors associated with the development of type 2 diabetes include the use of diabetogenic immunosuppre...
BACKGROUND Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clinical evidence of therapeutic strategies in such patients is still lacking. A recent randomized, placebo-controlled trial in patients with type 2 diabetes with high cardiovascular...
AIM To evaluate the long-term safety and efficacy of canagliflozin as add-on therapy in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycaemic control with teneligliptin monotherapy. METHODS This open-label 52-week study was conducted in Japan. Patients received canagliflozin 100 mg added to teneligliptin 20 mg orally once daily for 52 weeks. The safety endpoint was the in...
AIMS The primary aim of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R) is to determine whether the favourable effects of inhibition of the sodium glucose co-transporter 2 (SGLT2) on blood glucose, blood pressure and body weight are accompanied by protection against adverse renal outcomes. MATERIALS AND METHODS CANVAS-R is a prospective, randomized, double-blind, placebo-co...
UNLABELLED Drugs that inhibit the sodium-glucose co-transporter-2 (SGLT2) are an exciting novel, insulin-independent treatment for diabetes that block glucose reabsorption from the proximal tubules of the kidney, leading to increased glucose excretion and lower blood glucose levels. Inhibition of SGLT2 activity also reduces sodium reabsorption, which together with glycosuria produces a mild diu...
Diabetic foot infection (DFI) is a common complication in diabetes patients, with infections being the leading cause of amputations. Staphylococcus aureus frequently found diabetic infections, which methicillin-resistant (MRSA) has become major clinical and epidemiological challenge. Since MRSA strains are resistant to most β-lactam antibiotics, also partially other treatment difficult costly. ...
Abstract Background/Introduction Individuals with type 2 diabetes mellitus (T2DM) are at a greater risk for experiencing cardiovascular (CV) and kidney events. Canagliflozin is sodium glucose co-transporter inhibitor that has demonstrated reduction of these events in participants T2DM or without history CV disease (CVD) both the CANVAS Program CREDENCE trial. Purpose To determine pooled effects...
Background: People with type 2 diabetes and chronic kidney disease experience a high burden of hypertension, but the magnitude consistency blood pressure (BP) lowering canagliflozin in this population are uncertain. Whether effects on cardiovascular outcomes vary by baseline BP or BP-lowering therapy is also unknown. Methods: The CREDENCE trial (Canagliflozin Renal Events Diabetes Established N...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید